



(11) **EP 0 772 619 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**07.06.2006 Bulletin 2006/23**

(51) Int Cl.:  
**C07H 21/00<sup>(2006.01)</sup> C12Q 1/68<sup>(2006.01)</sup>**  
**A61K 31/70<sup>(2006.01)</sup>**

(21) Application number: **95911630.2**

(86) International application number:  
**PCT/US1995/001570**

(22) Date of filing: **07.02.1995**

(87) International publication number:  
**WO 1996/002555 (01.02.1996 Gazette 1996/06)**

(54) **IMMUNOMODULATORY OLIGONUCLEOTIDES**  
**IMMUNOMODULATORISCHE OLIGONUKLEOTIDE**  
**OLIGONUCLEOTIDES IMMUNOMODULATEURS**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL**  
**PT SE**

(30) Priority: **15.07.1994 US 276358**

(43) Date of publication of application:  
**14.05.1997 Bulletin 1997/20**

(60) Divisional application:  
**01202811.4 / 1 167 377**  
**01202813.0 / 1 167 378**  
**01202814.8 / 1 167 379**  
**04026517.5**  
**04105677.1**

(73) Proprietors:  
• **The University of Iowa Research Foundation**  
**Iowa City**  
**IA 52319 (US)**  
• **United States of America, as represented by the**  
**Secretary, Department of Health and Human**  
**Services**  
**Washington, DC (US)**  
• **Coley Pharmaceutical Group, Inc.**  
**Wellesley, MA 02481 (US)**

(72) Inventors:  
• **KRIEG, Arthur, M.**  
**Iowa City, IA 52319 (US)**  
• **KLINMAN, Dennis**  
**Potomac,**  
**MD 20854 (US)**  
• **STEINBERG, Alfred D.**  
**Potomac,**  
**MD 20854 (US)**

(74) Representative: **Jump, Timothy John Simon et al**  
**Venner Shipley LLP**  
**20 Little Britain**  
**London EC1A 7DH (GB)**

(56) References cited:  
**EP-A- 0 468 520**

- **JOURNAL OF VIROLOGY**, vol.64, no.2, February 1990 pages 757 - 766 D.OTT ET AL. 'Sequence Analysis of Amphotropic and 10A1 Murine Leukemia Viruses : Close Relationship to Mink Cell Focus-Inducing Viruses.'
- **JOURNAL OF VIROLOGY**, vol.46, no.1, April 1983 pages 204 - 211 R.REPASKE ET AL. 'Nucleotide Sequence of the env-Specific Segment of NFS-Th-1 Xenotropic Murine Leukemia Virus.'
- **JOURNAL OF VIROLOGY**, vol.53, no.2, February 1985 L.WOLFF ET AL. 'Sequence Comparisons of the Anemia- and Polycythemia-Inducing Strains of Friend'
- **JOURNAL OF VIROLOGY**, vol.64, no.11, November 1990 pages 5491 - 5499 A.C.MASSEY ET AL. 'Origin of Pathogenic Determinants of Recombinant Murine Leukemia Viruses : Analysis of Bxv-1-Related Xenotropic Viruses from CWD Mice.'
- **R.F.BRANDA ET AL.: 'IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1' BIOCHEMICAL PHARMACOLOGY** vol. 45, no. 10, 1993, pages 2037 - 2043

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 772 619 B1**

- MOJCIK ET AL.: 'ADMINISTRATION OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE ANTISENSE TO MURINE ENDOGENOUS RETROVIRAL MCF ENV CAUSES IMMUNE EFFECTS IN VIVO IN A SEQUENCE-SPECIFIC MANNER' CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY vol. 67, no. 2, 1993, pages 130 - 136
- KATAOKA T; ET AL: 'ANTITUMOR ACTIVITY OF SYNTHETIC OLIGONUCLEOTIDES WITH SEQUENCES FROM CDNA ENCODING PROTEINS OF MYCOBACTERIUM-BOVIS BCG' JAPAN JOURNAL OF CANCER RESEARCH vol. 83, 1992, pages 244 - 247
- KURAMOTO E; YANO O; SHIMADA S: 'INDUCTION OF T-CELL MEDIATED IMMUNITY AGAINST METHA FIBROSARCOMA BY INTRATUMORAL INJECTIONS OF A BACILLUS CALMETTE-GUERIN NUCLEIC ACID FRACTION' CANCER IMMUNOLOGY AND IMMUNOTHERAPY vol. 34, 1992, pages 283 - 288

## Description

## Background of the Invention

5 DNA binds to cell membrane and is internalized

[0001] In the 1970's, several investigators reported the binding of high molecular weight DNA to cell membranes (Lerner, R.A., W. Meinke, and D.A. Goldstein. 1971. "Membrane-associated DNA in the cytoplasm of diploid human lymphocytes". *Proc. Natl. Acad. Sci. USA* 68:1212; Agrawal, S.K., R.W. Wagner, P.K. McAllister, and B. Rosenberg. 10 1975. "Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy". *Proc. Natl. Acad. Sci. USA* 72:928). In 1985 Bennett et al. presented the first evidence that DNA binding to lymphocytes is similar to a ligand receptor interaction: binding is saturable, competitive, and leads to DNA endocytosis and degradation (Bennett, R.M., G.T. Gabor, and M.M. Merritt. 1985. "DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA". *J. Clin. Invest.* 76:2182). Like 15 DNA, oligodeoxyribonucleotides (ODNs) are able to enter cells in a saturable, sequence independent, and temperature and energy dependent fashion (reviewed in Jaroszewski, J.W., and J.S. Cohen. 1991. "Cellular uptake of antisense oligodeoxynucleotides". *Advanced Drug Delivery Reviews* 6:235; Akhtar, S., Y. Shoji, and R.L. Juliano. 1992. "Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides". In: *Gene Regulation: Biology of Antisense RNA and DNA*. R.P. Erickson, and J.G. Izant, eds. Raven Press, Ltd. New York, pp. 133; and Zhao, Q., T. Waldschmidt, E. Fisher, C.J. Herrera, and A.M. Krieg., 1994. "Stage specific oligonucleotide 20 uptake in murine bone marrow B cell precursors". *Blood*. 84:3660). No receptor for DNA or ODN uptake has yet been cloned, and it is not yet clear whether ODN binding and cell uptake occurs through the same or a different mechanism from that of high molecular weight DNA.

[0002] Lymphocyte ODN uptake has been shown to be regulated by cell activation. Spleen cells stimulated with the B cell mitogen LPS had dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A.M., F. Gmelig-Meyling, M.F. Gourley, W.J. Kisch, L.A. Chrisey, and A.D. Steinberg. 1991. "Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible". *Antisense Research and Development* 1:161).

30 Immune effects of nucleic acids

[0003] Several polynucleotides have been extensively evaluated as biological response modifiers. Perhaps the best example is poly (I,C) which is a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity (Talmadge, J.E., J. Adams, H. Phillips, M. Collins, B. Lenz, M. Schneider, E. Schlick, R. Ruffmann, R.H. Wiltout, 35 and M.A. Chirigos. 1985. "Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose". *Cancer Res.* 45:1058; Wiltout, R.H., R.R. Salup, T.A. Twilley, and J.E. Talmadge. 1985. "Immunomodulation of natural killer activity by polyribonucleotides". *J. Biol. Resp. Mod* 4:512; Krown, S.E. 1986. "Interferons and interferon inducers in cancer treatment". *Sem. Oncol.* 13:207; and Ewel, C.H., S.J. Urba, W.C. Kopp, J.W. Smith II, R.G. Steis, J.L. Rossio, D.L. Longo, M.J. Jones, W.G. Alvord, C.M. Pinsky, J.M. Beveridge, K.L. McNitt, 40 and S.P. Creekmore. 1992. "Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects". *Canc. Res.* 52:3005). It appears that this murine NK activation may be due solely to induction of IFN  $\beta$  secretion (Ishikawa, R., and C.A. Biron. 1993. "IFN induction and associated changes in splenic leukocyte distribution". *J. Immunol.* 150:3713). This activation was specific for the ribose sugar since deoxyribose was ineffective. Its potent in vitro antitumor activity led to several clinical 45 trials using poly (I,C) complexed with poly-L-lysine and carboxymethylcellulose (to reduce degradation by RNase) (Talmadge, J.E., et al., 1985. cited *supra*; Wiltout, R.H., et al., 1985. cited *supra*; Krown, S.E., 1986. cited *supra*; and Ewel, C.H., et al., 1992. cited *supra*). Unfortunately, toxic side effects have thus far prevented poly (I,C) from becoming a useful therapeutic agent.

[0004] Guanine ribonucleotides substituted at the C8 position with either a bromine or a thiol group are B cell mitogens and may replace "B cell differentiation factors" (Feldbush, T.L., and Z.K. Ballas. 1985. "Lymphokine-like activity of 8-mercaptopguanosine: induction of T and B cell differentiation". *J. Immunol.* 134:3204; and Goodman, M.G. 1986. "Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptopguanosine". *J. Immunol.* 136:3335). 8-mercaptopguanosine and 8-bromoguanosine also can substitute for the cytokine requirement for the generation of MHC restricted CTL (Feldbush, T.L., 55 1985. cited *supra*), augment murine NK activity (Koo, G.C., M.E. Jewell, C.L. Manyak, N.H. Sigal, and L.S. Wicker. 1988. "Activation of murine natural killer cells and macrophages by 8-bromoguanosine". *J. Immunol.* 140:3249), and synergize with IL-2 in inducing murine LAK generation (Thompson, R.A., and Z.K. Ballas. 1990. "Lymphokine-activated killer (LAK) cells. V. 8-Mercaptopguanosine as an IL-2-sparing agent in LAK generation". *J. Immunol.* 145:3524). The NK and LAK

augmenting activities of these C8-substituted guanosines appear to be due to their induction of IFN (Thompson, R.A., et al. 1990. cited *supra*). Recently, a 5' triphosphorylated thymidine produced by a mycobacterium was found to be mitogenic for a subset of human  $\gamma\delta$  T cells (Constant, P., F. Davodeau, M.-A. Peyrat, Y. Poquet, G. Puzo, M. Bonneville, and J.-J. Fournie. 1994. "Stimulation of human  $\gamma\delta$  T cells by nonpeptidic mycobacterial ligands" *Science* 264:267). This report indicated the possibility that the immune system may have evolved ways to preferentially respond to microbial nucleic acids.

**[0005]** Several observations suggest that certain DNA structures may also have the potential to activate lymphocytes. For example, Bell et al. reported that nucleosomal protein-DNA complexes (but not naked DNA) in spleen cell supernatants caused B cell proliferation and immunoglobulin secretion (Bell, D.A., B. Morrison, and P. VandenBygaert. 1990. "Immunogenic DNA-related factors". *J. Clin Invest.* 85:1487). In other cases, naked DNA has been reported to have immune effects. For example, Messina et al. have recently reported that 260 to 800 bp fragments of poly (dG)-(dC) and poly (dG-dC) were mitogenic for B cells (Messina, J.P., G.S. Gilkeson, and D.S. Pisetsky. 1993. "The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens". *Cell. Immunol.* 147:148). Tokunaga, et al. have reported that dG-dC induces  $\gamma$ -IFN and NK activity (Tokunaga, S. Yamamoto, and K. Namba. 1988. "A synthetic single-stranded DNA, poly(dG,dC), induces interferon- $\alpha/\beta$  and - $\gamma$ , augments natural killer activity, and suppresses tumor growth" *Jpn. J. Cancer Res.* 79:682). Aside from such artificial homopolymer sequences, Pisetsky et al. reported that pure mammalian DNA has no detectable immune effects, but that DNA from certain bacteria induces B cell activation and immunoglobulin secretion (Messina, J.P., G.S. Gilkeson, and D.S. Pisetsky. 1991. "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA". *J. Immunol.* 147:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindrome sequences can activate NK cells (Yamamoto, S., T. Yamamoto, T. Kataoka, E. Kuramoto, O. Yano, and T. Tokunaga. 1992. "Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity". *J. Immunol.* 148:4072; Kuramoto, E., O. Yano, Y. Kimura, M. Baba, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1992. "Oligonucleotide sequences required for natural killer cell activation". *Jpn. J. Cancer Res.* 83:1128; and EPO 468 520 A2).

**[0006]** Several phosphorothioate modified ODN have been reported to induce in vitro or in vivo B cell stimulation (Tanaka, T., C.C. Chu, and W.E. Paul. 1992. "An antisense oligonucleotide complementary to a sequence in Iy2b increases  $\gamma$ 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion". *J. Exp. Med.* 175:597; Branda, R.F., A.L. Moore, L. Mathews, J.J. McCormack, and G. Zon. 1993. "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1". *Biochem. Pharmacol.* 45:2037; McIntyre, K.W., K. Lombard-Gillooly, J.R. Perez, C. Kunsch, U.M. Sarmiento, J.D. Larigan, K.T. Landreth, and R. Narayanan. 1993. "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF- $\kappa$   $\beta$  T65 causes sequence-specific immune stimulation". *Antisense Res. Develop.* 3:309; and Pisetsky, D.S., and C.F. Reich. 1993. "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus". *Life Sciences* 54:101). These reports do not suggest a common structural motif or sequence element in these ODN that might explain their effects.

#### The CREB/ATF family of transcription factors and their role in replication

**[0007]** The cAMP response element binding protein (CREB) and activating transcription factor (ATF) or CREB/ATF family of transcription factors is a ubiquitously expressed class of transcription factors of which 11 members have so far been cloned (reviewed in de Groot, R-P., and P. Sassone-Corsi: "Hormonal control of gene expression: Multiplicity and versatility of cyclic adenosine 3',5'-monophosphate-responsive nuclear regulators". *Mol. Endocrin.* 7:145,1993; Lee, K.A.W., and N. Masson: "Transcriptional regulation by CREB and its relatives". *Biochim. Biophys. Acta* 1174:221,1993.). They all belong to the basic region/leucine zipper (bZip) class of proteins. All cells appear to express one or more CREB/ATF proteins, but the members expressed and the regulation of mRNA splicing appear to be tissue-specific. Differential splicing of activation domains can determine whether a particular CREB/ATF protein will be a transcriptional inhibitor or activator. Many CREB/ATF proteins activate viral transcription, but some splicing variants which lack the activation domain are inhibitory. CREB/ATF proteins can bind DNA as homo- or hetero- dimers through the cAMP response element, the CRE, the consensus form of which is the unmethylated sequence TGACGTC (binding is abolished if the CpG is methylated) (Iguchi-Arigo, S.M.M., and W. Schaffner "CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation". *Genes & Develop.* 3:612,1989.).

**[0008]** The transcriptional activity of the CRE is increased during B cell activation (Xie. H. T.C. Chiles, and T.L. Rothstein: "Induction of CREB activity via the surface Ig receptor of B cells". *J. Immunol.* 151:880, 1993.). CREB/ATF proteins appear to regulate the expression of multiple genes through the CRE including immunologically important genes

such as *fos*, *jun*, *B*, *Rb-1*, *IL-6*, *IL-1* (Tsukada, J., K. Saito, W.R. Waterman, A.C. Webb, and P.E. Auron: "Transcription factors NF- $\kappa$ B and CREB recognize a common essential site in the human interleukin 1 $\beta$  gene". *Mol. Cell. Biol.* 14: 7285, 1994; Gray, G.D., O.M. Hernandez, D. Hebel, M. Root, J.M. Pow-Sang, and E. Wickstrom: "Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice". *Cancer Res.* 53:577, 1993), IFN- $\beta$  (Du, W., and T. Maniatis: "An ATF/CREB binding site protein is required for virus induction of the human interferon B gene". *Proc. Natl. Acad. Sci. USA* 89:2150, 1992), TGF- $\beta$ 1 (Asiedu, C.K., L. Scott, R.K. Assoian, M. Ehrlich: "Binding of AP-1/CREB proteins and of MDPB to contiguous sites downstream of the human TGF- $\beta$  gene". *Biochim. Biophys. Acta* 1219: 55, 1994.), TGF- $\beta$ 2, class II MHC (Cox, P.M., and C.R. Goding: "An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DR $\alpha$  promoter and activation by SV40 T-antigen". *Nucl. Acids Res.* 20: 4881, 1992.), E-selectin, GM-CSF, CD-8 $\alpha$ , the germline Ig $\alpha$  constant region gene, the TCR V $\beta$  gene, and the proliferating cell nuclear antigen (Huang, D., P.M. Shipman-Appasamy, D.J. Orten, S.H. Hinrichs, and M.B. Prystowsky: "Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRB-binding proteins in interleukin 2-stimulated T lymphocytes". *Mol. Cell. Biol.* 14:4233, 1994.). In addition to activation through the cAMP pathway, CREB can also mediate transcriptional responses to changes in intracellular Ca<sup>++</sup> concentration (Sheng, M., G. McFadden, and M.E. Greenberg: "Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB". *Neuron* 4:571, 1990).

**[0009]** The role of protein-protein interactions in transcriptional activation by CREB/ATF proteins appears to be extremely important. Activation of CREB through the cyclic AMP pathway requires protein kinase A (PKA), which phosphorylates CREB<sup>341</sup> on ser<sup>133</sup> and allows it to bind to a recently cloned protein, CBP (Kwok, R.P.S., J.R. Lundblad, J.C. Chirvia, J.P. Richards, H.P. Bachinger, R.G. Brennan, S.G.E. Roberts, M.R. Green, and R.H. Goodman: "Nuclear protein CBP is a coactivator for the transcription factor CREB". *Nature* 370:223, 1994; Arias, J., A.S. Alberts, P. Brindle, F.X. Claret, T. Smea, M. Karin, J. Feramisco, and M. Montminy: "Activation of cAMP and mitogen responsive genes relies on a common nuclear factor". *Nature* 370:226, 1994.). CBP in turn interacts with the basal transcription factor TFIIB causing increased transcription. CREB also has been reported to interact with dTAFII 110, a TATA binding protein-associated factor whose binding may regulate transcription (Ferrerri, K., G. Gill, and M. Montminy: "The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex". *Proc. Natl. Acad. Sci. USA* 91:1210, 1994.). In addition to these interactions, CREB/ATF proteins can specifically bind multiple other nuclear factors (Hoeffler, J.P., J.W. Lustbader, and C.-Y. Chen: "Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions". *Mol. Endocrinol.* 5:256, 1991) but the biologic significance of most of these interactions is unknown. CREB is normally thought to bind DNA either as a homodimer or as a heterodimer with several other proteins. Surprisingly, CREB monomers constitutively activate transcription (Krajewski, W., and K.A.W. Lee: "A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator". *Mol. Cell. Biol.* 14:7204, 1994.).

**[0010]** Aside from their critical role in regulating cellular transcription, it has recently been shown that CREB/ATF proteins are subverted by some infectious viruses and retroviruses, which require them for viral replication. For example, the cytomegalovirus immediate early promoter, one of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y.-N., S. Crawford, J. Stall, D.R. Rawlins, K.-T. Jeang, and G.S. Hayward: "The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements". *J. Virol.* 64:264, 1990). At least some of the transcriptional activating effects of the adenovirus E1A protein, which induces many promoters, are due to its binding to the DNA binding domain of the CREB/ATF protein, ATF-2, which mediates E1A inducible transcription activation (Liu, F., and M.R. Green: "Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains". *Nature* 368:520, 1994). It has also been suggested that E1A binds to the CREB-binding protein, CBP (Arany, Z., W.R. Sellers, D.M. Livingston, and R. Eckner: "E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators". *Cell* 77:799, 1994). Human T lymphotropic virus-I (HTLV-1), the retrovirus which causes human T cell leukemia and tropical spastic paresis, also requires CREB/ATF proteins for replication. In this case, the retrovirus produces a protein, Tax, which binds to CREB/ATF proteins and redirects them from their normal cellular binding sites to different DNA sequences (flanked by G- and C-rich sequences) present within the HTLV transcriptional enhancer (Paca-Uccaralertkun, S., L.-J. Zhao, N. Adya, J.V. Cross, B.R. Cullen, I.M. Boros, and C.-Z. Giam: "In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax". *Mol. Cell. Biol.* 14:456, 1994; Adya, N., L.-J. Zhao, W. Huang, I. Boros, and C.-Z. Giam: "Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB". *Proc. Natl. Acad. Sci. USA* 91:5642, 1994).

## 55 Summary of the Invention

**[0011]** The instant invention is based on the finding that certain oligonucleotides containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes as evidenced by *in vitro* and *in vivo* data. Based on this finding, the

invention features, in one aspect, novel immunostimulatory oligonucleotide compositions.

[0012] Accordingly, in a first aspect, the present invention provides a composition, for use as a medicament, comprising a vaccine and a synthetic immunostimulatory oligonucleotide of at least 8 bases in size, which contains at least one unmethylated CpG dinucleotide and is an adjuvant for the vaccine.

[0013] In a second aspect the invention provides the use of a composition in accordance with the first aspect of the invention, for the manufacture of a medicament for vaccinating a subject.

[0014] In a further aspect, the invention provides the use of a synthetic immunostimulatory oligonucleotide of at least 8 bases in size, which contains at least one unmethylated CpG dinucleotide, for the manufacture of a medicament for administration to a subject in conjunction with a vaccine, as an adjuvant for the vaccine.

[0015] Preferred embodiments and aspects of the invention are described in the attached claims.

[0016] In a preferred embodiment, an *immunostimulatory oligonucleotide* is synthetic, between 8 to 100 bases in size and contains a consensus mitogenic CpG motif represented by the formula:



wherein C and G are unmethylated,  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are nucleotides and a GCG trinucleotide sequence is not present at or near the 5' and 3' termini.

[0017] For facilitating uptake into cells, CpG containing immunostimulatory oligonucleotides are preferably in the range of 8 to 40 bases in size. Prolonged immunostimulation can be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized oligonucleotides. Enhanced immunostimulatory activity has been observed where  $X_1 X_2$  is the dinucleotide GpA and/or  $X_3 X_4$  is the dinucleotide is most preferably TpC or also TpT. Further enhanced immunostimulatory activity has been observed where the consensus motif  $X_1 X_2 C G X_3 X_4$  is preceded on the 5' end by a T.

[0018] In another aspect, the invention features useful methods, which are based on the immunostimulatory activity of the oligonucleotides. For example, lymphocytes can either be obtained from a subject and stimulated *ex vivo* upon contact with an appropriate oligonucleotide; or a non-methylated CpG containing oligonucleotide can be administered to a subject to facilitate *in vivo* activation of a subject's lymphocytes. Activated lymphocytes, stimulated by the methods described herein (e.g. either *ex vivo* or *in vivo*), can boost a subject's immune response. The immunostimulatory oligonucleotides can therefore be used to treat, prevent or ameliorate an immune system deficiency (e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject). In addition, immunostimulatory oligonucleotides can also be administered as a vaccine adjuvant, to stimulate a subject's response to a vaccine.

[0019] Other features and advantages of the invention will become more apparent from the following detailed description and claims.

## Detailed Description of the Invention

### Definitions

[0020] As used herein, the following terms and phrases shall have the meanings set forth below:

[0021] An "oligonucleotide" or "oligo" shall mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). The term "oligonucleotide" as used herein refers to both oligoribonucleotides (ORNs) and oligodeoxyribonucleotides (ODNs). The term "oligonucleotide" shall also include oligonucleosides (i.e. an oligonucleotide minus the phosphate) and any other organic base containing polymer. Oligonucleotides can be obtained from existing nucleic acid sources (e.g. genomic or cDNA), but are preferably synthetic (e.g. produced by oligonucleotide synthesis).

[0022] A "stabilized oligonucleotide" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g. via an *exo*- or *endo*-nuclease). Preferred stabilized oligonucleotides of the instant invention have a modified phosphate backbone. Especially preferred oligonucleotides have a phosphorothioate modified phosphate backbone (i.e. at least one of the phosphate oxygens is replaced by sulfur). Other stabilized oligonucleotides include: nonionic DNA analogs, such as alkyl- and aryl- phosphonates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

[0023] An "immunostimulatory oligonucleotide", "immunostimulatory CpG containing oligonucleotide", or "CpG ODN" refer to an oligonucleotide, which contains a cytosine, guanine dinucleotide sequence and stimulates (e.g. has a mitogenic effect) on vertebrate lymphocytes. Preferred immunostimulatory oligonucleotides are between 8 to 100 bases in size and contain a consensus mitogenic CpG motif represented by the formula:



wherein C and G are unmethylated,  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are nucleotides and a GCG trinucleotide sequence is not present at or near the 5' and 3' termini.

5 **[0024]** Preferably the immunostimulatory oligonucleotides range between 8 to 40 bases in size. In addition, the immunostimulatory oligonucleotides are preferably stabilized oligonucleotides, particularly preferred are phosphorothioate stabilized oligonucleotides. In one preferred embodiment,  $X_1 X_2$  is the dinucleotide GpA. In another preferred embodiment,  $X_3 X_4$  is preferably the dinucleotide TpC or also TpT. In a particularly preferred embodiment, the consensus motif  $X_1 X_2 C G X_3 X_4$  is preceded on the 5' end by a T. Particularly preferred consensus sequences are TGACGTT or TGACGTC.

10 **[0025]** Prolonged immunostimulation can be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized.

**[0026]** "Palindromic sequence" shall mean an inverted repeat (i.e. a sequence such as ABCDEE'D'CB'A' in which A and A' are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double stranded structures.

15 **[0027]** An "oligonucleotide delivery complex" shall mean an oligonucleotide associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells). Examples of oligonucleotide delivery complexes include oligonucleotides associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor).  
20 Preferred complexes must be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target cell. However, the complex should be cleavable under appropriate conditions within the cell so that the oligonucleotide is released in a functional form.

**[0028]** An "immune system deficiency" shall mean a disease or disorder in which the subject's immune system is not functioning in normal capacity or in which it would be useful to boost a subject's immune response for example to eliminate a tumor or cancer (e.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas) or a viral (e.g. HIV, herpes), fungal (e.g. *Candida sp.*), bacterial or parasitic (e.g. Leishmania, Toxoplasma) infection in a subject.

25 **[0029]** A "disease associated with immune system activation" shall mean a disease or condition caused or exacerbated by activation of the subject's immune system. Examples include systemic lupus erythematosus, sepsis and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

30 **[0030]** A "subject" shall mean a human or vertebrate animal including a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat, mouse, etc.

#### Certain Unmethylated CpG Containing Oligos Have B Cell Stimulatory Activity As Shown in vitro and in vivo

35 **[0031]** In the course of investigating the lymphocyte stimulatory effects of two antisense oligonucleotides specific for endogenous retroviral sequences, using protocols described in the attached Examples 1 and 2, it was surprisingly found that two out of twenty-four "controls" (including various scrambled, sense, and mismatch controls for a panel of "antisense" ODN) also mediated B cell activation and IgM secretion, while the other "controls" had no effect.

40 **[0032]** Two observations suggested that the mechanism of this B cell activation by the "control" ODN may not involve antisense effects 1) comparison of vertebrate DNA sequences listed in GenBank showed no greater homology than that seen with non-stimulatory ODN and 2) the two controls showed no hybridization to Northern blots with 10 µg of spleen poly A+ RNA. Resynthesis of these ODN on a different synthesizer or extensive purification by polyacrylamide gel electrophoresis or high pressure liquid chromatography gave identical stimulation, eliminating the possibility of an impurity. Similar stimulation was seen using B cells from C3H/HeJ mice, eliminating the possibility that lipopolysaccharide (LPS) contamination could account for the results.

45 **[0033]** The fact that two "control" ODN caused B cell activation similar to that of the two "antisense" ODN raised the possibility that all four ODN were stimulating B cells through some non-antisense mechanism involving a sequence motif that was absent in all of the other nonstimulatory control ODN. In comparing these sequences, it was discovered that all of the four stimulatory ODN contained ODN dinucleotides that were in a different sequence context from the non-stimulatory control.

50 **[0034]** To determine whether the CpG motif present in the stimulatory ODN was responsible for the observed stimulation, over 300 ODN ranging in length from 5 to 42 bases that contained methylated, unmethylated, or no CpG dinucleotides in various sequence contexts were synthesized. These ODNs, including the two original "controls" (ODN 1 and 2) and two originally synthesized as "antisense" (ODN 3D and 3M; Krieg, A.M. *J. Immunol.* 143:2448 (1989)), were then examined for in vitro effects on spleen cells (representative sequences are listed in Table 1). Several ODN that contained CpG dinucleotides induced B cell activation and IgM secretion; the magnitude of this stimulation typically could be increased by adding more CpG dinucleotides (Table 1; compare ODN 2 to 2a or 3D to 3Da and 3Db). Stimulation

did not appear to result from an antisense mechanism or impurity. ODN caused no detectable activation of  $\gamma\delta$  or other T cell populations.

**[0035]** Mitogenic ODN sequences uniformly became nonstimulatory if the CpG dinucleotide was mutated (Table 1; compare ODN 1 to 1a; 3D to 3Dc; 3M to 3Ma; and 4 to 4a) or if the cytosine of the CpG dinucleotide was replaced by 5-methylcytosine (Table 1; ODN 1b,2b,2c,3Dd, and 3Mb). In contrast, methylation of other cytosines did not reduce ODN activity (ODN 1c,2d, 3De and 3Mc). These data confirmed that a CpG motif is the essential element present in ODN that activate B cells.

**[0036]** In the course of these studies, it became clear that the bases flanking the CpG dinucleotide played an important role in determining the B cell activation induced by an ODN. The optimal stimulatory motif was determined to consist of a CpG flanked by two 5' purines (preferably a GpA dinucleotide) and two 3' pyrimidines (preferably a TpT or TpC dinucleotide). Mutations of ODN to bring the CpG motif closer to this ideal improved stimulation (e.g. compare ODN 2 to 2e; 3M to 3Md) while mutations that disturbed the motif reduced stimulation (e.g. compare ODN 3D to 3Df; 4 to 4b, 4c and 4d). On the other hand, mutations outside the CpG motif did not reduce stimulation (e.g. compare ODN 1 to 1d; 3D to 3Dg; 3M to 3Me).

**[0037]** Of those tested, ODNs shorter than 8 bases were non-stimulatory (e.g. ODN 4e). Among the forty-eight 8 base ODN tested, the most stimulatory sequence identified was TCAACGTT (ODN 4) which contains the self complementary "palindrome" AACGTT. In further optimizing this motif, it was found that ODN containing Gs at both ends showed increased stimulation, particularly if the ODN were rendered nuclease resistant by phosphorothioate modification of the terminal internucleotide linkages. ODN 1585 (5' GGGGTCAACGTTCAAGGGGG 3' (SEQ ID NO:1)), in which the first two and last five internucleotide linkages are phosphorothioate modified caused an average 25.4 fold increase in mouse spleen cell proliferation compared to an average 3.2 fold increase in proliferation induced by ODN 1638, which has the same sequence as ODN 1585 except that the 10 Gs at the two ends are replaced by 10 As. The effect of the G-rich ends is *cis*; addition of an ODN with poly G ends but no CpG motif to cells along with 1638 gave no increased proliferation.

**[0038]** Other octamer ODN containing a 6 base palindrome with a TpC dinucleotide at the 5' end were also active if they were dose to the optimal motif (e.g. ODN 4b,4c). Other dinucleotides at the 5' end gave reduced stimulation (eg ODN 4f; all sixteen possible dinucleotides were tested). The presence of a 3' dinucleotide was insufficient to compensate for the lack of a 5' dinucleotide (eg. ODN 4g). Disruption of the palindrome eliminated stimulation in octamer ODN (eg., ODN 4h), but palindromes were not required in longer ODN.

Table 1: Oligonucleotide Stimulation of B Cells

ODN	Sequence (5' to 3')†	Stimulation Index'	
		<sup>3</sup> H Uridine	IgM Production
1 (SEQ ID NO: 2)	GCTAGACGTTAGCGT:	6.1 ± 0.8	17.9 ± 3.6
1a (SEQ. ID NO: 3)	.....T.....	1.2 ± 0.2	1.7 ± 0.5
1b (SEQ ID NO: 4)	.....Z.....	1.2 ± 0.1	1.8 ± 0.0
1c (SEQ ID NO: 5)	.....Z.....	10.3 ± 4.4	9.5 ± 1.8
1d (SEQ ID NO: 6)	..AT.....GAGC.	13.0 ± 2.3	18.3 ± 7.5
2 (SEQ ID NO: 7)	ATGGAAGGTCCAGCGTTCTC	2.9 ± 0.2	13.6 ± 2.0
2a (SEQ ID NO: 8)	..C..CTC..G.....	7.7 ± 0.8	24.2 ± 3.2
2b (SEQ ID NO: 9)	..Z..CTC.ZG..Z.....	1.6 ± 0.5	2.8 ± 2.2
2e (SEQ ID NO: 10)	..Z..CTC..G.....	3.1 ± 0.6	7.3 ± 1.4
2d (SEQ ID NO: 11)	..C..CTC..G.....Z..	7.4 ± 1.4	27.7 ± 5.4
2e (SEQ ID NO: 12)	.....A.....	5.6 ± 2.0	ND
3D (SEQ ID NO: 13)	GAGAAAGCTGGACCTTCAT	4.9 ± 0.5	19.9 ± 3.6
3Da (SEQ ID NO: 14)	.....C.....	66 ± 1.5	33.9 ± 6.9
3Db (SEQ ID NO: 15)	.....C.....G...	10.1 ± 2.8	25.4 ± 0.8
3Dc (SEQ ID NO: 16)	... C.A.....	1.0 ± 0.1	1.2 ± 0.5
3Dd (SEQ ID NO: 17)	.....z.....	12 ± 0.2	1.0 ± 0.4
3De (SEQ ID NO: 18)	.....Z.....	4.4 ± 1.2	18.8 ± 4.4
3Df (SEQ ID NO: 19)	.....A.....	1.6 ± 0.1	7.7 ± 0.4



Table continued

ODN	Sequence (5' to 3')†	Stimulation Index'	
		<sup>3</sup> H Uridine	IgM Production
3Dg (SEQ ID NO: 20)	.....CC.G.ACTG..	6.1±1.5	18.6±1.5
3M (SEQ ID NO: 21)	TCCATGT <u>C</u> GGTCCTGATGCT	4.1 ± 0.2	232±4.9
3Ma (SEQ ID NO:22)	.....CT.....	0.9±0.1	1.8±0.5
3Mb (SEQ ID NO:23)	.....Z.....	1.3± 0.3	1.5±0.6
3Mc (SEQ ID NO:24)	..... <u>Z</u> .....	5.4±1.5	8.5±2.6
3Md (SEQ ID NO: 25)	.....A <u>T</u> .....	17.2±9.4	ND
3Me (SEQ ID NO: 26)	.....C.A.	3.6±0.2	142±5.2
4	TCAAC <u>G</u> TT	6.1 ± 1.4	19.2 ± 5.2
4a	....GC..	1.1 ± 0.2	15 ± 1.1
4b	...G <u>C</u> G <u>C</u> ..	4.5± 0.2	9.6 ± 3.4
4c	...T <u>C</u> G <u>A</u> ..	2.7± 1.0	ND
4d	.. TT <u>AA</u>	1.3 ± 0.2	ND
4e	-.....	1.3 ± 0.2	1.1 ± 0.5
4f	c.....	3.9 ± 1.4	ND
4g	--.....CT	1.4 ± 0.3	ND
4h	.....C	1.2 ± 0.2	ND
LPS		7.8 ± 2.5	4.8 ± 1.0

' Stimulation indexes are the means and std. dev. derived from at least 3 separate experiments, and are compared to wells cultured with no added ODN. ND - not done. CpG dinucleotides are underlined. Dots indicate identity; dashes indicate deletions. Z indicates 5 methyl cytosine.)

[0039] The kinetics of lymphocyte activation were investigated using mouse spleen cells. When the cells were pulsed at the same time as ODN addition and harvested just four hours later, there was already a two-fold increase in <sup>3</sup>H uridine incorporation. Stimulation peaked at 12-48 hours and then decreased. After 24 hours, no intact ODN were detected, perhaps accounting for the subsequent fall in stimulation when purified B cells with or without anti-IgM (at a submitogenic dose) were cultured with CpG ODN, proliferation was found to synergistically increase about 10-fold by the two mitogens in combination after 48 hours. The magnitude of stimulation was concentration dependent and consistently exceeded that of LPS under optimal conditions for both. Oligonucleotides containing a nuclease resistant phosphorothioate backbone were approximately two hundred times more potent than unmodified oligonucleotides.

[0040] Cell cycle analysis was used to determine the proportion of B cells activated by CpG-ODN. CpG-ODN induced cycling in more than 95% of B cells (Table 2). Splenic B lymphocytes sorted by flow cytometry into CD23- (marginal zone) and CD23+ (follicular) subpopulations were equally responsive to ODN- induced stimulation, as were both resting and activated populations of B cells isolated by fractionation over Percoll gradients. These studies demonstrated that CpG-ODN induce essentially all B cells to enter the cell cycle.

Table 2: Cell Cycle Analysis with CpG ODN

Treatment	Percent of cells in		
	G0	G1	SA+G2+M
Media	97.6	2.4	0.02
ODN 1a a	95.2	4.8	0.04
ODN 1d	2.7	74.4	22.9
ODN 3Db	3.5	76.4	20.1
LPS (30 µg/ml)	17.3	70.5	12.2

[0041] The mitogenic effects of CpG ODN on human cells, were tested on peripheral blood mononuclear cells (PBMCs) obtained from two patients with chronic lymphocytic leukemia (CLL), as described in Example 1. Control ODN containing

no CpG dinucleotide sequence showed no effect on the basal proliferation of 442 cpm and 874 cpm (proliferation measured by  $^3\text{H}$  thymidine incorporation) of the human cells. However, a phosphorothioate modified CpG ODN 3Md (SEQ m NO: 25) induced increased proliferation of 7210 and 86795 cpm respectively in the two patients at a concentration of just 1  $\mu\text{M}$ . Since these cells had been frozen, they may have been less responsive to the oligos than fresh cells *in vivo*. In addition, cells from CLL patients typically are non-proliferating, which is why traditional chemotherapy is not effective.

[0042] Certain B cell lines such as WEHI-231 are induced to undergo growth arrest and/or apoptosis in response to crosslinking of their antigen receptor by anti-IgM (Jakway, J.P. et al., "Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide and other bacterial products" *J. Immunol.* 137: 2225 (1986); Tsubata, T., J. Wu and T. Honjo: B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40." *Nature* 364: 645 (1993)). WEHI-231 cells are rescued from this growth arrest by certain stimuli such as LPS and by the CD40 ligand. ODN containing the CpG motif were also found to protect WEHI-231 from anti-IgM induced growth arrest, indicating that accessory cell populations are not required for the effect.

[0043] To better understand the immune effects of unmethylated CpG ODN, the levels of cytokines and prostaglandins *in vitro* and *in vivo* were measured. Unlike LPS, CpG ODN were not found to induce purified macrophages to produce prostaglandin PGE2. In fact, no apparent direct effect of CpG ODN was detected on either macrophages or T cells. *In vivo* or in whole spleen cells, no significant increase in the following interleukins: IL-2, IL-3, IL-4, or IL-10 was detected within the first six hours. However, the level of IL-6 increased strikingly within 2 hours in the serum of mice injected with CpG ODN. Increased expression of IL-12 and interferon gamma (EFN- $\gamma$ ) by spleen cells was also detected within the first two hours.

[0044] To determine whether CpG ODN can cause *in vivo* immune stimulation, DBA/2 mice were injected once intraperitoneally with PBS or phosphorothioate CpG or non-CpG ODN at a dose of 33 mg/kg (approximately 500  $\mu\text{g}$ /mouse). Pharmacokinetic studies in mice indicate that this dose of phosphorothioate gives levels of approximately 10  $\mu\text{g}$ /g in spleen tissue (within the effective concentration range determined from the *in vitro* studies described herein) for longer than twenty-four hours (Agrawal, S. et al. (1991) *Proc. Natl. Acad. Sci. USA* 91:7595). Spleen cells from mice were examined twenty-four hours after ODN injection for expression of B cells surface activation markers Ly-6A/E, B1a-1, and class II MHC using three color flow cytometry and for their spontaneous proliferation using  $^3\text{H}$  thymidine. Expression of all three activation markers was significantly increased in B cells from mice injected with CpG ODN, but not from mice injected with PBS or non-CpG ODN. Spontaneous  $^3\text{H}$  thymidine incorporation was increased by 2-6 fold in spleen cells from mice injected with the stimulatory ODN compared to PBS or non-CpG ODN-injected mice. After 4 days, serum IgM levels in mice injected with CpG ODN *in vivo* were increased by approximately 3-fold compared to controls. Consistent with the inability of these agents to activate T cells, there was minimal change in T cell expression of the IL-2R or CD-44.

[0045] Degradation of phosphodiester ODN in serum is predominantly mediated by 3' exonucleases, while intracellular ODN degradation is more complex, involving 5' and 3' exonucleases and endonucleases. Using a panel of ODN bearing the 3D sequence with varying numbers of phosphorothioate modified linkages at the 5' and 3' ends, it was empirically determined that two 5' and five 3' modified linkages are required to provide optimal stimulation with this CpG ODN.

#### Unmethylated CpG Containing Oligos Have NK Cell Stimulatory Activity

[0046] As described in further detail in Example 4, experiments were conducted to determine whether CpG containing oligonucleotides stimulated the activity of natural killer (NK) cells in addition to B cells. As shown in Table 3, a marked induction of NK activity among spleen cells cultured with CpG ODN 1 and 3Dd was observed. In contrast, there was relatively no induction in effectors that had been treated with non-CpG control ODN.

**Table 3: Induction Of NK Activity By CpG Oligodeoxynucleotides (ODN)**

	% YAC-1 Specific Lysis*		% 2C11 Specific Lysis	
	Effector:	Target	Effector:	Target
ODN	50:1	100:1	50:1	100:1
None	-1.1	-1.4	15.3	16.6
1	16.1	24.5	38.7	47.2
3Dd	17.1	27.0	37.0	40.0
non-CpG ODN	-1.6	-1.7	14.8	15.4

#### Neutralizing Activity of Methylated CpG Containing Oligos

[0047] B cell mitogenicity of ODN in which cytosines in CpG motifs or elsewhere were replaced by 5-methylcytosine

were tested as described in Example 1. As shown in Table 1 above, ODN containing methylated CpG motifs were non-mitogenic (Table 1; ODN 1c, 2f, 3De, and 3Mc). However, methylation of cytosines other than in a CpG dinucleotide retained their stimulatory properties (Table 1, ODN 1d, 2d, 3Df, and 3Md).

#### 5 Immunoinhibitory Activity of Oligos Containing a GCG Trinucleotide Sequence at or near both termini

**[0048]** In some cases, ODN containing CpG dinucleotides that are not in the stimulatory motif described above were found to block the stimulatory effect of other mitogenic CpG ODN. Specifically the addition of an atypical CpG motif consisting of a GCG near or at the 5' and/or 3' end of CpG ODN actually inhibited stimulation of proliferation by other  
10 CpG motifs. Methylation or substitution of the cytosine in a GCG motif reverses this effect. By itself, a GCG motif in an ODN has a modest mitogenic effect, though far lower than that seen with the preferred CpG motif.

#### Proposed Mechanisms of Action of Immunostimulatory, Neutralizing and Immunoinhibitory Oligonucleotides

**[0049]** Unlike antigens that trigger B cells through their surface Ig receptor, CpG-ODN did not induce any detectable  $\text{Ca}^{2+}$  flux, changes in protein tyrosine phosphorylation, or IP 3 generation. Flow cytometry with FITC-conjugated ODN with or without a CpG motif was performed as described in Zhao, Q et al., (*Antisense Research and Development* 3: 53-66 (1993)), and showed equivalent membrane binding, cellular uptake, efflux, and intracellular localization. This suggests that there may not be cell membrane proteins specific for CpG ODN. Rather than acting through the cell  
20 membrane, that data suggests that unmethylated CpG containing oligonucleotides require cell uptake for activity: ODN covalently linked to a solid Teflon support were nonstimulatory, as were biotinylated ODN immobilized on either avidin beads or avidin coated petri dishes. CpG ODN conjugated to either FITC or biotin retained full mitogenic properties, indicating no steric hindrance.

**[0050]** The optimal CpG motif (TGACGTT/C is identical to the CRE (cyclic AMP response element). Like the mitogenic effects of CpG ODN, binding of CREB to the CRE is abolished if the central CpG is methylated. Electrophoretic mobility shift assays were used to determine whether CpG ODN, which are single stranded, could compete with the binding of B cell CREB/ATF proteins to their normal binding site, the doublestranded CRE. Competition assays demonstrated that single stranded ODN containing CpG motifs could completely compete the binding of CREB to its binding site, while ODN without CpG motifs could not. These data support the conclusion that CpG ODN exert their mitogenic effects through interacting with one or more B cell CREB/ATF proteins in some way. Conversely, the presence of GCG sequences or other atypical CPG motifs near the 5' and/or 3' ends of ODN likely interact with CREB/ATF proteins in a way that does not cause activation, and may even prevent it.

**[0051]** The stimulatory CpG motif is common in microbial genomic DNA, but quite rare in vertebrate DNA. In addition, bacterial DNA has been reported to induce B cell proliferation and immunoglobulin (Ig) production, while mammalian DNA does not (Messina, J.P. et al., *J Immunol.* 147:1759 (1991)). Experiments further described in Example 3, in which methymon of bacterial DNA with CpG methylase was found to abolish mitogenicity, demonstrates that the difference in CpG status is the cause of B cell stimulation by bacterial DNA. This data supports the following conclusion: that unmethylated CpG dinucleotides present within bacterial DNA are responsible for the stimulatory effects of bacterial DNA.

**[0052]** Teleologically, it appears likely that lymphocyte activation by the CpG motif represents an immune defense mechanism that can thereby distinguish-bacterial from host DNA. Host DNA would induce little or no lymphocyte activation due to it CpG suppression and methylation. Bacterial DNA would cause selective lymphocyte activation in infected tissues. Since the CpG pathway synergizes with B cell activation through the antigen receptor, B cells bearing antigen receptor specific for bacterial antigens would receive one activation signal through cell membrane Ig and a second signal from bacterial DNA, and would therefore tend to be preferentially activated. The interrelationship of this pathway with  
45 other pathways of B cell activation provide a physiologic mechanism employing a polyclonal antigen to induce antigen-specific responses.

#### Method for Making Immunostimulatory Oligos

**[0053]** For use in the instant invention, oligonucleotides can be synthesized de novo using any of a number of procedures well known in the art. For example, the  $\beta$ -cyanoethyl phosphoramidite method (S.L. Beaucage and M.H. Caruthers, (1981) *Tet. Let.* 22:1859); nucleoside H-phosphonate method (Garegg et al., (1986) *Tet. Let.* 27: 4051-4054; Froehler et al., (1986) *Nucl. Acid Res.* 14: 5399-5407; Garegg et al., (1986) *Tet. Let.* 27: 4055-4058, Gaffney et al., (1988) *Tet. Let.* 29:2619-2622). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available  
55 in the market. Alternatively, oligonucleotides can be prepared from existing nucleic acid sequences (e.g. genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

**[0054]** For use *in vivo*, oligonucleotides are preferably relatively resistant to degradation (e.g. via endo- and exonucleases). Oligonucleotide stabilization can be accomplished via phosphate backbone modifications. A preferred sta-

bilized oligonucleotide has a phosphorothioate modified backbone. The pharmacokinetics of phosphorothioate ODN show that they have a systemic half-life of forty-eight hours in rodents and suggest that they may be useful for *in vivo* applications (Agrawal, S. et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:7595). Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H phosphonate chemistries. Aryl- and alkyl- phosphonates can be made e.g. (as described in U.S. Patent No. 4,469,863); and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A. (1990) *Chem Rev.* 90:544; Goodchild, J. (1990) *Bioconjugate Chem.* 1:165).

[0055] For administration *in vivo*, oligonucleotides may be associated with a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells to form an "oligonucleotide delivery complex". Oligonucleotides can be ionically, or covalently associated with appropriate molecules using techniques which are well known in the art. A variety of coupling or crosslinking agents can be used e.g. protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Oligonucleotides can alternatively be encapsulated in liposomes or virosomes using well-known techniques.

[0056] The present invention is further illustrated by the following Examples which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

#### Therapeutic Uses of Immunostimulatory Oligos

[0057] Based on their immunostimulatory properties, oligonucleotides containing at least one unmethylated CpG dinucleotide can be administered to a subject *in vivo* to treat an "immune system deficiency". Alternatively, oligonucleotides containing at least one unmethylated CpG dinucleotide can be contacted with lymphocytes (e.g. B cells or NK cells) obtained from a subject having an immune system deficiency *ex vivo* and activated lymphocytes can then be reimplanted in the subject.

[0058] Immunostimulatory oligonucleotides can be administered to a subject in conjunction with the vaccine, as an adjuvant, to boost a subject's immune system to effect better response from the vaccine, slightly before or at the same time as the vaccine.

[0059] CpG ODN also increased natural killer cell activity in both human and murine cells. Induction of NK activity may likewise be beneficial in cancer immunotherapy.

[0060] For use in therapy, an effective amount of an appropriate oligonucleotide alone or formulated as an oligonucleotide delivery complex can be administered to a subject by any mode allowing the oligonucleotide to be taken up by the appropriate target cells (e.g. B-cells and NK cells). Preferred routes of administration include oral and transdermal (e.g. via a patch). Examples of other routes of administration include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.). The injection can be in a bolus or a continuous infusion.

[0061] An oligonucleotide alone or as an oligonucleotide delivery complex can be administered in conjunction with a pharmaceutically acceptable carrier. As used herein, the phrase "pharmaceutically acceptable carrier" is intended to include substances that can be coadministered with an oligonucleotide or an oligonucleotide delivery complex and allows the oligonucleotide to perform its intended function. Examples of such carriers include solutions, solvents, dispersion media, delay agents, emulsions and the like. The use of such media for pharmaceutically active substances are well known in the art. Any other conventional carrier suitable for use with the oligonucleotides falls within the scope of the instant invention.

[0062] The language "effective amount" of an oligonucleotide refers to that amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of an oligonucleotide containing at least one unmethylated CpG for treating an immune system deficiency could be that amount necessary to eliminate a tumor, cancer, or bacterial, viral or fungal infection. An effective amount for use as a vaccine adjuvant could be that amount useful for boosting a subject's immune response to a vaccine. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular oligonucleotide being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular oligonucleotide without necessitating undue experimentation.

[0063] The studies reported above indicate that unmethylated CpG containing oligonucleotides are directly mitogenic for lymphocytes (e.g. B cells and NK cells). Together with the presence of these sequences in bacterial DNA, these results suggest that the underrepresentation of CpG dinucleotides in animal genomes, and the extensive methylation of cytosines present in such may be explained by the existence of an immune defense mechanism that can distinguish bacterial from host DNA. Host DNA would commonly be present in many anatomic regions and areas of inflammation due to apoptosis (cell death), but generally induces little or no lymphocyte activation. However, the presence of bacterial

DNA containing unmethylated CpG motifs can cause lymphocyte activation precisely in infected anatomic regions, where it is beneficial. This novel activation pathway provides a rapid alternative to T cell dependent antigen specific B cell activation. However, it is likely that B cell activation would not be totally nonspecific. B cells bearing antigen receptors specific for bacterial products could receive one activation signal through cell membrane Ig, and a second from bacterial DNA, thereby more vigorously triggering antigen specific immune responses.

#### Therapeutic Uses of Oligos Containing GCG Trinucleotide Sequences at or Near Both Termini

**[0064]** Based on their interaction with CREB/ATF, oligonucleotides containing GCG trinucleotide sequences at or near both termini have antiviral activity, independent of any antisense effect due to complementarity between the oligonucleotide and the viral sequence being targeted. Based on this activity, an effective amount of inhibitory oligonucleotides can be administered to a subject to treat or prevent a viral infection.

#### **EXAMPLES**

##### Example 1: Effects of ODNs on B Cell Total RNA Synthesis and Cell Cycle

**[0065]** B cells were purified from spleens obtained from 6-12 wk old specific pathogen free DBA/2 or BXSB mice (bred in the University of Iowa animal care facility; no substantial strain differences were noted) that were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lympholyte M (Cedarlane Laboratories, Hornby, Ontario, Canada) ("B cells"). B cells contained fewer than 1% CD4<sup>+</sup> or CD8<sup>+</sup> cells. 8x10<sup>4</sup> B cells were dispensed in triplicate into 96 well microtiter plates in 100  $\mu$ l RPMI containing 10% FBS (heat inactivated to 65°C for 30 min.), 50  $\mu$ M 2-mercaptoethanol, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 2 mM L-glutamate. 20  $\mu$ M ODN were added at the start of culture for 20 h at 37°C, cells pulsed with 1  $\mu$ Ci of <sup>3</sup>H uridine, and harvested and counted 4 hr later. Ig secreting B cells were enumerated using the ELISA spot assay after culture of whole spleen cells with ODN at 20  $\mu$ M for 48 hr. Data, reported in Table 1, represent the stimulation index compared to cells cultured without ODN. Cells cultured without ODN gave 687 cpm, while cells cultured with 20  $\mu$ g/ml LPS (determined by titration to be the optimal concentration) gave 99,699 cpm in this experiment. <sup>3</sup>H thymidine incorporation assays showed similar results, but with some nonspecific inhibition by thymidine released from degraded ODN (Matson. S and A.M. Krieg (1992) Nonspecific suppression of <sup>3</sup>H-thymidine incorporation by control oligonucleotides. *Antisense Research and Development* 2:325).

**[0066]** For cell cycle analysis, 2 X 10<sup>6</sup> B cells were cultured for 48 hr. in 2 ml tissue culture medium alone, or with 30  $\mu$ g/ml LPS or with the indicated phosphorothioate modified ODN at 1  $\mu$ M. Cell cycle analysis was performed as described in (Darzynkiewicz, Z. et al., *Proc. Natl. Acad. Sci. USA* 78:2881 (1981)).

**[0067]** To test the mitogenic effects of CpG ODN on human cells, peripheral blood monocyte cells (PBMCs) were obtained from two patients with chronic lymphocytic leukemia (CLL), a disease in which the circulating cells are malignant B cells. Cells were cultured for 48 hrs and pulsed for 4 hours with tritiated thymidine as described above.

##### Example 2: Effects of ODN on Production of IgM from B cells

**[0068]** Single cell suspensions from the spleens of freshly killed mice were treated with anti-Thy1, anti-CD4, and anti-CD8 and complement by the method of Leibson et al., *J. Exp. Med* 154:1681 (1981)). Resting B cells (<.02% T cell contamination) were isolated from the 63 - 70% band of a discontinuous Percoll gradient by the procedure of DeFranco et al, *J. Exp. Med* 155:1523 (1982). These were cultured as described above in 30  $\mu$ M ODN or 20  $\mu$ g/ml LPS for 48 hr. The number of B cells actively secreting IgM was maximal at this time point, as determined by ELISpot assay (Klinman, D.M. et al. *J. Immunol.* 144:506 (1990)). In that assay, B cells were incubated for 6 hrs on anti-Ig coated microtiter plates. The Ig they produced (>99% IgM) was detected using phosphatase-labelled anti-Ig (Southern Biotechnology Associated, Birmingham, AL). The antibodies produced by individual B cells were visualized by addition of BCIP (Sigma Chemical Co., St. Louis MO) which forms an insoluble blue precipitate in the presence of phosphatase. The dilution of cells producing 20 - 40 spots/well was used to determine the total number of antibody-secreting B cells/sample. All assays were performed in triplicate. In some experiments, culture supernatants were assayed for IgM by ELISA, and showed similar increases in response to CpG-ODN.

table 1

##### Example 3: B cell Stimulation by Bacterial DNA

**[0069]** DBA/2 B cells were cultured with no DNA or 50  $\mu$ g/ml of a) *Micrococcus lysodeikticus*; b) NZB/N mouse spleen; and c) NFS/N mouse spleen genomic DNAs for 48 hours, then pulsed with <sup>3</sup>H thymidine for 4 hours prior to cell harvest.

Duplicate DNA samples were digested with DNase I for 30 minutes at 37 C prior to addition to cell cultures. E coli DNA also induced an 8.8 fold increase in the number of IgM secreting B cells by 48 hours using the ELISA-spot assay.

5 [0070] DBA/2 B cells were cultured with either no additive, 50 µg/ml LPS or the ODN 1; 1a; 4; or 4a at 20 uM. Cells were cultured and harvested at 4, 8, 24 and 48 hours. BXSB cells were cultured as in Example 1 with 5, 10, 20,40 or 80 µM of ODN 1; 1a; 4; or 4a or LPS. In this experiment, wells with no ODN had 3833 cpm. Each experiment was performed at least three times with similar results. Standard deviations of the triplicate wells were <5%.

#### Example 4: Effects of ODN on natural killer (NK) activity

10 [0071] 10 x 10<sup>6</sup> C57BL/6 spleen cells were cultured in two ml RPMI (supplemented as described for Example 1) with or without 40 µM CpG or non-CpG ODN for forty-eight hours. Cells were washed, and then used as effector cells in a short term <sup>51</sup>Cr release assay with YAC-1 and 2C11, two NK sensitive target cell lines (Ballas, Z. K. et al. (1993) *J. Immunol.* 150:17). Effector cells were added at various concentrations to 10<sup>4</sup> <sup>51</sup>Cr-labeled target cells in V-bottom microtiter plates in 0.2 ml, and incubated in 5% CO<sub>2</sub> for 4 hr. at 37°C. Plates were then centrifuged, and an aliquot of  
15 the supernatant counted for radioactivity. Percent specific lysis was determined by calculating the ratio of the <sup>51</sup>Cr released in the presence of effector cells minus the <sup>51</sup>Cr released when the target cells are cultured alone, over the total counts released after cell lysis in 2% acetic acid minus the <sup>51</sup>Cr cpm released when the cells are cultured alone.

#### Example 5: In vivo studies with CpG phosphorothioate ODN

20 [0072] Mice were weighed and injected IP with 0.25 ml of sterile PBS or the indicated phosphorothioate ODN dissolved in PBS. Twenty four hours later, spleen cells were harvested, washed, and stained for flow cytometry using phycoerythrin conjugated 6B2 to gate on B cells in conjunction with biotin conjugated anti Ly-6A/E or anti-Ia<sup>d</sup> (Pharmingen, San Diego, CA) or anti-Bla-1 (Hardy, R.R. et al., *J. Exp. Med.* 159:1169 (1984)). Two mice were studied for each condition and  
25 analyzed individually.

#### Example 6 Titration of Phosphorothioate ODN for B Cell Stimulation

30 [0073] B cells were cultured with phosphorothioate ODN with the sequence of control ODN 1a or the CpG ODN 1d and 3Db and then either pulsed after 20 hr with <sup>3</sup>H uridine or after 44 hr with <sup>3</sup>H thymidine before harvesting and determining cpm.

#### Example 7 Rescue of B Cells From Apoptosis

35 [0074] WEHI-231 cells (5 x 10<sup>4</sup>/well) were cultured for 1 hr. at 37 C in the presence or absence of LPS or the control ODN 1a or the CpG ODN 1d and 3Db before addition of anti-IgM (1 µ/ml). Cells were cultured for a further 20 hr. before a 4 hr. pulse with 2 µCi/well <sup>3</sup>H thymidine. In this experiment, cells with no ODN or anti-IgM gave 90.4 x 10<sup>3</sup> by addition of anti-IgM. The phosphodiester ODN shown in Table 1 gave similar protection, though with some nonspecific suppression due to ODN degradation. Each experiment was repeated at least 3 times with similar results.

#### Example 8 In vivo induction of IL-6

40 [0075] DBA/2 female mice (2 mos. old) were injected IP with 500 µg CpG or control phosphorothioate ODN. At various time points after injection, the mice were bled. Two mice were studied for each time point. IL-6 was measured by Elisa, and IL-6 concentration was calculated by comparison to a standard curve generated using recombinant EL-6. The  
45 sensitivity of the assay was 10 pg/ml. Levels were undetectable after 8 hr.

#### Example 9 Binding of B cell CREB/ATF to a radiolabelled doublestranded CRE probe (CREB)

50 [0076] Whole cell extracts from CH12.LX B cells showed 2 retarded bands when analyzed by EMSA with the CRE probe (free probe is off the bottom of the figure). The CREB/ATF protein(s) binding to the CRE were competed by the indicated amount of cold CRE, and by single-stranded CpG ODN, but not by non-CpG ODN.

#### Equivalents

55 [0077] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

[0078]

5

(1) GENERAL INFORMATION:

- (i) APPLICANT: Arthur M. Krieg, M.D.
- (ii) TITLE OF INVENTION: IMMUNOMODULATORY OLIGONUCLEOTIDES
- (iii) NUMBER OF SEQUENCES: 27
- (iv) CORRESPONDENCE ADDRESS:

10

- (A) ADDRESSEE: LAHIVE & COCKFIELD
- (B) STREET: 60 STATE STREET, SUITE 510
- (C) CITY: BOSTON
- (D) STATE: MASSACHUSETTS
- (E) COUNTRY: USA
- (F) ZIP: 02109-1875

15

(v) COMPUTER READABLE FORM:

20

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: ASCII text

25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: US
- (B) FILING DATE:
- (C) CLASSIFICATION:

30

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: ARNOLD, BETH B.
- (B) REGISTRATION NUMBER: 35,430
- (C) REFERENCE/DOCKET NUMBER: UIZ-013CP

35

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (617)227-7400
- (B) TELEFAX: (617)227-5941

40

(2) INFORMATION FOR SEQ ID NO: 1:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: DNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
GGGGTCAACG TTCAGGGGGG 20

55

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEMOS: single
- (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
GCTAGACGTT AGCGT 15

10

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
GCTAGATGTT AGCGT 15

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

30

- (ii) MOLECULE TYPE: DNA
- (ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 7
- (D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

35

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
GCTAGANGTT AGCGT 15

40

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45

50

- (ii) MOLECULE TYPE: DNA
- (ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 13
- (D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

55

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:



GCTAGACGTT AGNGT 15

(2) INFORMATION FOR SEQ ID NO:6:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  
GCATGACGTT GAGCT 15

15

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  
ATGGAAGGTC CAGCGTTCTC 20

25

(2) INFORMATION FOR SEQ ID NO:8:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- 35 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (xi) SEQUENCE DESCRIPTION: SBQ ID NO:8:  
ATCGACTCTC GAGCGTTCTC 20

40

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- 55 (B) LOCATION: 3
- (D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
(B) LOCATION: 10  
(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

5 (ix) FEATURE:

(A) NAME/KEY: misc\_feature  
(B) LOCATION: 14  
(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
ATNGACTCTN GAGNGTTCTC 20

(2) INFORMATION FOR SEQ ID NO:10:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA  
(ix) FEATURE:

25

(A) NAME/KEY: misc\_feature  
(B) LOCATION: 3  
(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

30 (xi) SEQUENCE DESCRIPTION: SBQ ID NO:10:  
ATNGACTCTC GAGCGTTCTC 20

(2) INFORMATION FOR SBQ ID NO:11:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: DNA  
(ix) FEATURE:

45 (A) NAME/KEY: misc\_feature  
(B) LOCATION: 18  
(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
ATCGACTCTC GAGCGTTNTC 20

(2) INFORMATION FOR SEQ ID NO:12:

55 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

5 ATGGAAGGTC CAACGTTCTC 20

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAGAACGCTG GACCTTCAT 20

20

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAGAACGCTC GACCTTCAT 20

30

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GAGAACGCTC GACCTTCGAT 20

40

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SBQ ID NO:16:

GAGCAAGCTG GACCTTCAT 20

50

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA  
(ix) FEATURE:

- (A) NAME/KEY: mise\_feature  
(B) LOCATION: 6  
15 (D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:  
QAOAANGCTG GACCTTCAT 20

20 (2) INFORMATION FOR SBQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- 30 (ii) MOLECULE TYPE: DNA  
(ix) FEATURE:

- (A) NAME/KEY: misc\_feature  
(B) LOCATION: 14  
35 (D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:  
GAGAACGCTG GACNTTCAT 20

(2) INFORMATION FOR SEQ ID NO:19:

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
45 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:  
50 GAGAACGATG GACCTTCAT 20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

55

- (A) LENGTH : 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  
GAGAACGCTC CAGCACTGAT 20

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:  
TCCATGTCGG TCCTGATGCT 20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:  
TCCATGCTGG TCCTGATGCT 20

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
(B) LOCATION: 8  
(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:  
TCCATGTNGG TCCTGATGCT 20

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

5

(A) NAME/KEY: misc\_feature

(B) LOCATION: 12

(D) OTHER INFORMATION: "N indicates 5 methyl cytosine"

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TCCATGTCGG TNCTGATGCT 20

(2) INFORMATION FOR SBQ ID NO:25:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCCATGACGT TCCTGATGCT 20

25

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDMMMSS: single

(D) TOPOL40W: linear

35

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TCCATGTCGG TCCTGCTGAT 20

(2) INFORMATION FOR SEQ ID NO:27:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

45

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

50

GGGGTCAAGT CTGAGGGGGG 20

## Claims

55

1. A composition, for use as a medicament, comprising a vaccine and a synthetic immunostimulatory oligonucleotide of at least 8 bases in size, which contains at least one unmethylated CpG dinucleotide and is an adjuvant for the vaccine.

2. A composition as claimed in claim 1, wherein the immunostimulatory oligonucleotide includes no more than 100 nucleotides.
3. A composition as claimed in claim 1 or 2, wherein the immunostimulatory oligonucleotide is a phosphodiester.
4. A composition as claimed in claim 1 or 2, wherein the immunostimulatory oligonucleotide is stabilised.
5. A composition as claimed in claim 4, wherein the immunostimulatory oligonucleotide has a phosphate backbone modification.
6. A composition as claimed in claim 5, wherein the modification is a phosphorothioate backbone modification.
7. A composition as claimed in any one of claims 1-6, wherein the immunostimulatory oligonucleotide is in the range of 8-40 bases in size.
8. A composition as claimed in any one of claims 1-7, wherein the immunostimulatory oligonucleotide does not contain a six base palindrome.
9. A composition as claimed in claim 8, wherein the immunostimulatory oligonucleotide includes more than 8 nucleotides.
10. A composition as claimed in any one of claims 1-9, wherein the immunostimulatory oligonucleotide has a mitogenic effect on vertebrate lymphocytes.
11. A composition as claimed in any one of claims 1-10, wherein the immunostimulatory oligonucleotide contains a sequence represented by the following formula:  

$$5' X_1 X_2 C G X_3 X_4 3'$$

wherein C and G are unmethylated and  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are nucleotides and a G C G trinucleotide sequence is not present at the 5' and 3' termini.
12. A composition as claimed in claim 11, wherein  $X_1$ ,  $X_2$  is a GpA dinucleotide.
13. A composition as claimed in claim 11 or 12, wherein  $X_3$ ,  $X_4$  is a TpC or TpT dinucleotide.
14. A composition as claimed in claim 11, 12 or 13, wherein the sequence is represented by the following formula:  

$$5' T X_1 X_2 C G X_3 X_4 3'$$

wherein C and G are unmethylated and  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are nucleotides.
15. A composition as claimed in any one of claims 1-14, wherein the immunostimulatory oligonucleotide is in the form of an oligonucleotide delivery complex.
16. A composition as claimed in claim 15, wherein the immunostimulatory oligonucleotide is associated with a sterol, a lipid, or a target cell specific binding agent.
17. A composition as claimed in claim 16, wherein the immunostimulatory oligonucleotide is associated with cholesterol, a cationic lipid, a virosome, a liposome or a ligand recognised by a target cell specific receptor.
18. A composition as claimed in claim 16, wherein the target cell specific binding agent is specific for a B-cell.
19. A composition as claimed in any one of claims 1-18, wherein the immunostimulatory oligonucleotide includes a plurality of unmethylated CpG dinucleotides.
20. A composition as claimed in any one of claims 1-19, further comprising a pharmaceutically acceptable carrier.

21. A composition as claimed in any one of the preceding claims, for use in treating:-
- (a) a human subject; or
  - (b) a non-human vertebrate animal, optionally, a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat or mouse.
22. A composition as claimed in any one of claims 1-21, for treating, preventing or ameliorating a disease or disorder in which a subject's immune system is not functioning normally, or in which it would be useful to boost a subject's immune response.
23. A composition as claimed in claim 22, wherein said disease or disorder is a tumour or cancer, or a viral, fungal, bacterial or parasitic infection.
24. Use of a composition as claimed in any one of claims 1-20, for the manufacture of a medicament for vaccinating a subject.
25. Use of a synthetic immunostimulatory oligonucleotide of at least 8 bases in size, which contains at least one un-methylated CpG dinucleotide, for the manufacture of a medicament for administration to a subject in conjunction with a vaccine, as an adjuvant for the vaccine.
26. A use as claimed in claim 25, wherein the immunostimulatory oligonucleotide is an immunostimulatory oligonucleotide as defined in any one of claims 2-19.
27. A use as claimed in claim 25 or 26, wherein said immunostimulatory oligonucleotide and said vaccine are for use in a method of treating, preventing or ameliorating a disease or disorder in which a subject's immune system is not functioning normally, or in which it would be useful to boost a subject's immune response.
28. A use as claimed in any one of claim 24-27, wherein the medicament boosts an immune response to a tumour or a cancer, or a viral, fungal, bacterial or parasitic infection.
29. Use of a composition as claimed in any one of claims 1-20 for the manufacture of a medicament for use in a method of treating, preventing or ameliorating a disease or disorder in which a subject's immune system is not functioning normally, or in which it would be useful to boost a subject's immune response.
30. A use as claimed in claim 27 or 29, wherein said disease or disorder is a tumor or cancer, or a viral, fungal, bacterial or parasitic infection.
31. A use as claimed in any one of claims 24-30 wherein the medicament is for activating a subject's B cells.
32. A use as claimed in claim 24 or 25, wherein the medicament is for use in treating, preventing, or ameliorating leukaemia.
33. A use as claimed in any one of claims 24-32, wherein the composition is formulated for oral, transdermal, subcutaneous, intravenous, parenteral, interperitoneal, or intrathecal administration.
34. Use of a composition as claimed in any one of claims 1-20, for the manufacture of a medicament for treating:-
- (a) a human subject; or,
  - (b) a non-human vertebrate animal, optionally, a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat or mouse.
35. A use as claimed in any one of claims 24-33, wherein the medicament is for treating:-
- (a) a human subject; or,
  - (b) a non-human vertebrate animal, optionally, a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat or mouse.



# Patentansprüche

1. Zusammensetzung zur Verwendung als Medikament, umfassend einen Impfstoff und ein synthetisches immunstimulierendes Oligonukleotid einer Größe von mindestens acht Basen, das mindestens ein unmethyliertes CpG-Dinukleotid enthält und ein Adjuvans für den Impfstoff ist.
2. Zusammensetzung nach Anspruch 1, wobei das immunstimulierende Oligonukleotid nicht mehr als 100 Nukleotide enthält.
3. Zusammensetzung nach Anspruch 1 oder 2, wobei das immunstimulierende Oligonukleotid ein Phosphodiester ist.
4. Zusammensetzung nach Anspruch 1 oder 2, wobei das immunstimulierende Oligonukleotid stabilisiert ist.
5. Zusammensetzung nach Anspruch 4, wobei das immunstimulierende Oligonukleotid eine Phosphatrückgratkettenmodifikation aufweist.
6. Zusammensetzung nach Anspruch 5, wobei die Modifikation eine Phosphorthioatrückgratkettenmodifikation ist.
7. Zusammensetzung nach einem der Ansprüche 1 - 6, wobei das immunstimulierende Oligonukleotid größenmäßig im Bereich von 8 - 40 Basen liegt.
8. Zusammensetzung nach einem der Ansprüche 1 - 7, wobei das immunstimulierende Oligonukleotid kein Sechsbasenpalindrom enthält.
9. Zusammensetzung nach Anspruch 8, wobei das immunstimulierende Oligonukleotid mehr als 8 Nukleotide enthält.
10. Zusammensetzung nach einem der Ansprüche 1 - 9, wobei das immunstimulierende Oligonukleotid auf vertebrae Lymphozyten eine mitogene Wirkung ausübt.
11. Zusammensetzung nach einem der Ansprüche 1 - 10, wobei das immunstimulierende Oligonukleotid eine Sequenz enthält, die durch folgende Formel dargestellt ist
 
$$5'X_1X_2CGX_3X_43'$$
 wobei C und G unmethyliert sind und  $X_1$ ,  $X_2$ ,  $X_3$  und  $X_4$  Nukleotide sind und eine GCG-Trinukleotidsequenz an den 5'- und 3'-Enden nicht vorhanden ist.
12. Zusammensetzung nach Anspruch 11, wobei  $X_1$ ,  $X_2$  ein GpA-Dinukleotid ist.
13. Zusammensetzung nach Anspruch 11 oder 12, wobei  $X_3$ ,  $X_4$  ein TpC- oder TpT-Dinukleotid ist.
14. Zusammensetzung nach Anspruch 11, 12 oder 13, wobei die Sequenz durch folgende Formel dargestellt ist
 
$$5' TX_1X_2CGX_3X_43'$$
 wobei C und G unmethyliert und  $X_1$ ,  $X_2$ ,  $X_3$  und  $X_4$  Nukleotide sind.
15. Zusammensetzung nach einem der Ansprüche 1 - 14, wobei das immunstimulierende Oligonukleotid in Form eines Oligonukleotidabgabekomplexes vorliegt.
16. Zusammensetzung nach Anspruch 15, wobei das immunstimulierende Oligonukleotid mit einem Sterol, einem Lipid oder einem zielzellenspezifischen Bindemittel assoziiert ist.
17. Zusammensetzung nach Anspruch 16, wobei das immunstimulierende Oligonukleotid mit Cholesterin, einem kationischen Lipid, einem Virosom, einem Liposom oder einem Liganden assoziiert ist, das bzw. der von einem zielzellenspezifischen Rezeptor erkannt wird.
18. Zusammensetzung nach Anspruch 16, wobei das zielzellenspezifische Bindemittel für eine B-Zelle spezifisch ist.

19. Zusammensetzung nach einem der Ansprüche 1 - 18, wobei das immunstimulierende Oligonukleotid mehrere unmethylierte CpG-Dinukleotide enthält.
- 5 20. Zusammensetzung nach einem der Ansprüche 1 - 19, des Weiteren einen pharmazeutisch akzeptablen Träger umfassend.
21. Zusammensetzung nach einem der vorhergehenden Ansprüche zur Verwendung bei der Behandlung
  - 10 (a) eines menschlichen Patienten oder
  - (b) eines nichtmenschlichen vertebraten Tiers, wahlweise eines Hundes, einer Katze, eines Pferds, einer Kuh, eines Schweins, eines Schafs, einer Ziege, eines Huhns, eines Affens, einer Ratte oder Maus.
22. Zusammensetzung nach einem der Ansprüche 1 - 21, zur Behandlung, Verhinderung oder Besserung einer Krankheit oder Beschwerde, wobei das Immunsystem eines Patienten/Tiers nicht normal funktioniert oder wobei es nützlich  
15 wäre, die Immunantwort eines Patienten/Tiers zu steigern.
23. Verbindung nach Anspruch 22, wobei die Krankheit oder Beschwerde ein Tumor oder Krebs oder eine Virus-, Pilz-, Bakterien- oder Parasiteninfektion ist.
- 20 24. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 - 20 für die Herstellung eines Medikaments zum Impfen eines Patienten/Tiers.
- 25 25. Verwendung eines synthetischen immunstimulierenden Oligonukleotids einer Größe von mindestens 8 Basen, das mindestens ein unmethyliertes CpG-Dinukleotid enthält, für die Herstellung eines Medikaments für die Verabreichung einem Patienten/Tier in Verbindung mit einem Impfstoff, als Adjuvans für den Impfstoff.
26. Verwendung nach Anspruch 25, wobei das immunstimulierende Oligonukleotid ein immunstimulierendes Oligonukleotid, wie in einem der Ansprüche 2 - 19 definiert, ist.
- 30 27. Verwendung nach Anspruch 25 oder 26, wobei das immunstimulierende Oligonukleotid und der Impfstoff zur Verwendung bei einer Methode zur Behandlung, Verhinderung oder Besserung einer Krankheit oder Beschwerde dienen, wobei das Immunsystem eines Patienten/Tiers nicht normal funktioniert oder wobei es nützlich wäre, die Immunantwort eines Patienten/Tiers zu steigern.
- 35 28. Verwendung nach einem der Ansprüche 24 - 27, wobei das Medikament eine Immunantwort auf einen Tumor oder Krebs oder eine Virus-, Pilz-, Bakterien- oder Parasiteninfektion steigert.
29. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 - 20 für Herstellung eines Medikaments zur Verwendung bei einer Methode zur Behandlung, Verhinderung oder Besserung einer Krankheit oder Beschwerde, wobei das Immunsystem eines Patienten/Tiers nicht normal funktioniert oder wobei es nützlich wäre, die Immunantwort eines Patienten/Tiers zu steigern.  
40
30. Verwendung nach Anspruch 27 oder 29, wobei die Krankheit oder Beschwerde ein Tumor oder Krebs oder eine Virus-, Pilz-, Bakterien- oder Parasiteninfektion ist.  
45
31. Verwendung nach einem der Ansprüche 24 - 30, wobei das Medikament zum Aktivieren der B-Zellen eines Patienten/Tiers dient.
- 50 32. Verwendung nach Anspruch 24 oder 25, wobei das Medikament zur Verwendung zur Behandlung, Verhinderung oder Besserung von Leukämie dient.
33. Verwendung nach einem der Ansprüche 24 - 32, wobei die Zusammensetzung für die orale, transdermale, subkutane, intravenöse, parenterale, interperitoneale oder intrathekale Verabreichung formuliert ist.
- 55 34. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 - 20 für die Herstellung eines Medikaments für die Behandlung
  - (a) eines menschlichen Patienten oder

(b) d'un animal non humain à vertèbres, par exemple d'un chien, d'un chat, d'un cheval, d'une vache, d'un porc, d'une chèvre, d'un poulet, d'un singe, d'un rat ou d'une souris.

35. Utilisation selon l'une des revendications 24 - 33, dans laquelle le médicament de traitement

(a) d'un patient humain ou

(b) d'un animal non humain à vertèbres, par exemple d'un chien, d'un chat, d'un cheval, d'une vache, d'un porc, d'une chèvre, d'un poulet, d'un singe, d'un rat ou d'une souris.

## Revendications

1. Composition conçue pour être utilisée comme un médicament qui comprend un vaccin et un oligonucléotide de synthèse immunostimulateur à 8 bases au minimum servant d'adjuvant du vaccin et contenant au moins un dinucléotide CpG non méthylé.

2. Composition selon la revendication 1, dans laquelle ledit oligonucléotide immunostimulateur ne comprend pas plus de 100 nucléotides.

3. Composition selon la revendication 1 ou 2, dans laquelle ledit oligonucléotide immunostimulateur est un phosphodiester.

4. Composition selon la revendication 1 ou 2, dans laquelle ledit oligonucléotide immunostimulateur est stabilisé.

5. Composition selon la revendication 4, dans laquelle ledit oligonucléotide immunostimulateur présente une modification au niveau du squelette phosphate.

6. Composition selon la revendication 5, dans laquelle ladite modification est une modification du squelette phosphorothioate.

7. Composition selon l'une quelconque des revendications 1-6, dans laquelle ledit oligonucléotide immunostimulateur contient de 8 à 40 bases.

8. Composition selon l'une quelconque des revendications 1-7, dans laquelle ledit oligonucléotide immunostimulateur ne contient pas une séquence palindromique de six bases.

9. Composition selon la revendication 8, dans laquelle ledit oligonucléotide immunostimulateur comporte plus de 8 nucléotides.

10. Composition selon l'une quelconque des revendications 1-9, dans laquelle ledit oligonucléotide immunostimulateur exerce un effet mitogène sur les lymphocytes de vertébrés.

11. Composition selon l'une quelconque des revendications 1-10, dans laquelle ledit oligonucléotide immunostimulateur contient une séquence représentée par la formule suivante:




où C et G ne sont pas méthylés,  $X_1$ ,  $X_2$ ,  $X_3$  et  $X_4$  représentent des nucléotides et les extrémités 5' et 3' ne comportent pas une séquence trinucleotidique de type GCG.

12. Composition selon la revendication 11, dans laquelle  $X_1 X_2$  représente un dinucléotide GpA.

13. Composition selon la revendication 11 ou 12, dans laquelle  $X_3 X_4$  représente un dinucléotide TpC ou TpT.

14. Composition selon la revendication 11, 12 ou 13, dans laquelle ladite séquence est représentée par la formule suivante:



où C et G ne sont pas méthylées et X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> et X<sub>4</sub> représentent des nucléotides.

- 5 15. Composition selon l'une quelconque des revendications 1-14, dans laquelle ledit oligonucléotide immunostimulateur est sous la forme d'un complexe de libération de l'oligonucléotide.
16. Composition selon la revendication 15, dans laquelle ledit oligonucléotide immunostimulateur est associé à un stérol, à un lipide ou à un agent qui se lie spécifiquement à une cellule cible.
- 10 17. Composition selon la revendication 16, dans laquelle ledit oligonucléotide immunostimulateur est associé au cholestérol, à un lipide cationique, à un virosome, à un liposome ou à un ligand reconnu par un récepteur spécifique d'une cellule cible.
18. Composition selon la revendication 16, dans laquelle l'agent qui se lie spécifiquement à une cellule cible est spécifique des lymphocytes B.
- 15 19. Composition selon l'une quelconque des revendications 1-18, dans laquelle ledit oligonucléotide immunostimulateur comprend une pluralité de dinucléotides CpG non méthylés.
- 20 20. Composition selon l'une quelconque des revendications 1-19, qui comprend également un véhicule pharmaceutiquement acceptable.
21. Composition selon l'une quelconque des revendications précédentes, qui est conçue pour être utilisée dans le traitement :-  
25       (a) d'un sujet humain ; ou  
         (b) d'un animal vertébré non humain qui correspond éventuellement à un chien, un chat, un cheval, une vache, un porc, un mouton, une chèvre, un poulet, un singe, un rat ou une souris.
- 30 22. Composition selon l'une quelconque des revendications 1-21, qui est conçue pour être utilisée dans le traitement, la prévention ou l'amélioration d'une affection ou d'une perturbation qui est associée à un fonctionnement anormal du système immunitaire d'un sujet ou pour laquelle un renforcement de la réponse immunitaire du sujet serait utile.
- 35 23. Composition selon la revendication 22, dans laquelle ladite affection ou perturbation est une tumeur ou un cancer, ou une infection virale, fongique, bactérienne ou parasitaire.
24. Utilisation d'une composition selon l'une quelconque des revendications 1-20 dans la fabrication d'un médicament utilisé pour vacciner un sujet.
- 40 25. Utilisation d'un oligonucléotide de synthèse immunostimulateur à 8 bases au minimum et contenant au moins un dinucléotide CpG non méthylé dans la fabrication d'un médicament conçu pour être administré à un sujet en conjonction avec un vaccin en tant qu'adjuvant dudit vaccin.
- 45 26. Utilisation selon la revendication 25, dans laquelle ledit oligonucléotide immunostimulateur est un oligonucléotide immunostimulateur tel que défini à l'une quelconque des revendications 2-19.
27. Utilisation selon la revendication 25 ou 26, dans laquelle ledit oligonucléotide immunostimulateur et ledit vaccin sont conçus pour être utilisés dans une méthode de traitement, de prévention ou d'amélioration d'une affection ou d'une perturbation qui est associée à un fonctionnement anormal du système immunitaire d'un sujet ou pour laquelle un renforcement de la réponse immunitaire du sujet serait utile.
- 50 28. Utilisation selon l'une quelconque des revendications 24-27, dans laquelle ledit médicament renforce la réponse immunitaire à une tumeur ou à un cancer, ou à une infection virale, fongique, bactérienne ou parasitaire.
- 55 29. Utilisation selon l'une quelconque des revendications 1-20 dans la fabrication d'un médicament conçu pour être utilisé dans une méthode de traitement, de prévention ou d'amélioration d'une affection ou d'une perturbation qui est associée à un fonctionnement anormal du système immunitaire d'un sujet ou pour laquelle un renforcement de la réponse immunitaire du sujet serait utile.

30. Utilisation selon la revendication 27 ou 29, dans laquelle ladite affection ou perturbation est une tumeur ou un cancer, ou une infection virale, fongique, bactérienne ou parasitaire.
- 5 31. Utilisation selon l'une quelconque des revendications 24-30, dans laquelle ledit médicament est conçu pour activer les lymphocytes B d'un sujet.
32. Utilisation selon la revendication 24 ou 25, dans laquelle ledit médicament est conçu pour être utilisé dans le traitement, la prévention ou l'amélioration d'une leucémie.
- 10 33. Utilisation selon l'une quelconque des revendications 24-32, dans laquelle ladite composition est formulée pour être administrée par voie orale, transdermique, sous-cutanée, intraveineuse, parentérale, interpéritonéale ou intrathécale.
- 15 34. Utilisation de la composition selon l'une quelconque des revendications 1-20 dans la fabrication d'un médicament indiqué dans le traitement :-
- (a) d'un sujet humain ; ou
- (b) d'un animal vertébré non humain qui correspond éventuellement à un chien, un chat, un cheval, une vache, un porc, un mouton, une chèvre, un poulet, un singe, un rat ou une souris.
- 20 35. Utilisation selon l'une quelconque des revendications 24-33, dans laquelle ledit médicament est indiqué dans le traitement :-
- (a) d'un sujet humain ; ou
- 25 (b) d'un animal vertébré non humain qui correspond éventuellement à un chien, un chat, un cheval, une vache, un porc, un mouton, une chèvre, un poulet, un singe, un rat ou une souris.
- 30
- 35
- 40
- 45
- 50
- 55